Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM12470 First-in-Human Study in Diabetes
NCT02302443Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2015
- Primary completion
- May 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of HM12470 in type 1 diabetes mellitus (T1D) and type 2 diabetes mellitus (T2DM) (6 cohorts), sponsored by Hanmi Pharmaceutical. Primary endpoint: Incidence and severity of treatment emergent adverse events at 1 month. Started Jan 2015; status: completed.
02
Drugs
HM12470
03
Conditions
type 1 diabetes mellitus (T1D)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02302443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02302443.